Summary & Overview
HCPCS J7682: Tobramycin Inhalation Solution, 300 mg Unit Dose
HCPCS Level II code J7682 identifies an FDA-approved, non-compounded tobramycin inhalation solution in unit dose form, billed per 300 milligrams and intended for administration through durable medical equipment (DME). This code matters nationally because inhaled tobramycin is a targeted therapy for patients with chronic or recurrent pulmonary infections where aerosolized aminoglycoside delivery can reduce bacterial load and exacerbations. Insurers and providers use this HCPCS code to capture the drug product and route of administration when provided with DME support.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for inhaled tobramycin, common sites of service, and payer coverage landscape. The publication summarizes typical billing practices, allowable reporting scenarios for unit dose, and common modifiers used with drug administration through DME (modifier details provided elsewhere). It also highlights benchmarking points and policy considerations relevant to national coverage and reimbursement processes for inhaled antibiotic therapies.
The piece is intended for billing professionals, revenue cycle leaders, and clinicians involved in pulmonary drug delivery, offering practical reference on code definition, clinical use cases, and what to expect when submitting claims for inhaled tobramycin supplied for nebulizer administration.
Billing Code Overview
HCPCS Level II code J7682 describes tobramycin inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, per 300 milligrams. The service type is inhaled antibiotic therapy delivered via a durable medical equipment (DME) nebulizer system. The typical site of service is outpatient or home-based administration using DME, including hospital outpatient departments, ambulatory infusion centers, and patient homes where nebulizer equipment is supplied.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with cystic fibrosis or bronchiectasis who requires inhaled antibiotic therapy for chronic Pseudomonas aeruginosa infection or acute pulmonary exacerbation. The patient presents to an outpatient pulmonary clinic or receives home health services; a respiratory therapist or nurse verifies the prescription for J7682 (tobramycin inhalation solution, FDA-approved, unit dose, per 300 mg) and provides education on administration via the patient’s DME nebulizer. The clinical workflow includes medication reconciliation, verification of diagnosis and prior authorization as needed, dispensing of unit-dose vials, demonstration of device setup and cleaning, documentation of lot number and expiration, and scheduling follow-up to assess response and adverse effects (renal function and ototoxicity monitoring when indicated). Typical sites of service are outpatient clinic infusion / respiratory therapy areas, home health settings, and durable medical equipment (DME) supplier locations where the medication is dispensed and training provided.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Not typically appended; placeholder when no other modifier applies |
11 |